Clinical and pharmacokinetic risk factors for high-dose methotrexate- induced toxicity in children with acute lymphoblastic leukemia - A logistic regression analysis

Acta Oncologica

Volumn 37, Issue 3, 1998, Pages 277-284

  Rask, Charlotte ^a,c   Albertioni, Freidoun ^b   Bentzen, Soeren M ^a   Schroeder, Henrik ^a   Peterson, Curt ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FOLINATE CALCIUM; LIVER ENZYME; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEMALE; HEMATOLOGIC DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRATHECAL DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LIVER; MALE; METHOTREXATE; MOUTH; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 0031780255     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698429586     Document Type: Article

References (32)

1. Abromowitch M, Ochs J, Pui CH, et al. High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude Total Therapy Study X. Med Pediatr Oncol 1988; 16: 297-303.
2. 2 in children with acute lymphoblastic leukemia. Cancer 1987; 60: 5-13.
3. Abromowitch M, Ochs J, Pui CH, Fairclough D, Murphy SB, Rivera GK. Efficacy of high-dose methotrexate in childhood acute lymphoblastic leukemia: analysis by contemporary risk classifications. Blood 1988; 71: 866-9.
4. Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 1977; 4: 87-101.
5. Sirotnak FM, Moccio DM. Pharmacokinetic basis for differences in methotrexate sensitivity of normal proliferative tissues in the mouse. Cancer Res 1980; 40: 1230-4.
6. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 1979; 3: 161-6.
7. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297: 630-4.
8. Perez C, Wang YM, Sutow WW, Herson J. Significance of the 48-hour plasma level in high-dose methotrexate regimens. Cancer Clin Trials 1978; 1: 107-11.
9. Borsi JD, Csáki C, Paál C, Ferencz T, Schuler D. Toxicity of high-dose methotrexate therapy. In: Riccardi R, Borsi J, eds. The role of clinical pharmacology in pediatric oncology. San Francisco: 6th Pharmacology Workshop Satellite to XXV SIOP Meeting, 1993: 112-8.
10. Christensen ML, Rivera GK, Crom WR, Hancock ML, Evans WE. Effect of hydration on methotrexate plasma concentration in children with acute lymphoblastic leukemia. J Clin Oncol 1988; 6: 797-801.
11. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12: 1667-72.
12. 2) in childhood malignancies: clinical tolerability and pharmacokinetics. Pediatr Hematol Oncol 1987; 4: 33-42.
13. Seidel H, Moe PJ, Nygaard R, Nygaard K, Brede W, Borsi JD. Evaluation of serious adverse events in patients treated with protocols including methotrexate infusions. Pediatr Hematol Oncol 1994; 11: 165-72.
14. Schroeder H, Heinsvig E. Enzymatic assay for methotrexate in erythrocytes. Scand J Clin Lab Invest 1985; 45: 657-9.
15. Albertioni F, Rask C, Eksborg S, et al. Evaluation of clinical assays for measuring high-dose methotrexate in plasma. Clin Chem 1996; 42: 39-44.
16. Sheiner LB, Beal SL. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm 1985; 13: 185-201.
17. Bieri D, Reeve RA, Champion GD, Addicoat L, Ziegler JB. The faces pain scale for the self-assessment of the severity of pain experienced by children: development, initial validation and preliminary investigation for ratio scale properties. Pain 1990; 41: 139-50.
18. Rask C, Albertioni F, Schroeder H, Peterson C. Oral mucositis in children with acute lymphoblastic leukemia alter high-dose methotrexate treatment without delayed elimination of methotrexate. Relation to pharmacokinetic parameters of methotrexate. Pediatr Hematol Oncol 1996; 13: 359-67.
19. Perez C, Sutow WW, Wang YM, Herson J. Evaluation of overall toxicity of high-dosage methotrexate regimens. Med Pediatr Oncol 1979; 6: 219-28.
20. Ishii E, Yamada S, Higuchi S, et al. Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia. Med Pediatr Oncol 1989; 17: 429-32.
21. Oliff A, Bleyer WA, Poplack DG. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother Pharmacol 1979; 2: 225-6.
22. Exadaktylos P, Reiss T, Schobess R, Hommann M, Höhne S. Beck A. Acute hepatotoxicity with intermediate-dose methotrexate in children with leukemia and non-Hodgkin's lymphoma. Klin Paediatr 1994; 206: 315-8.
23. McIntosh S, Davidson DL, O'Brien RT, Pearson HA. Methotrexate hepatotoxicity in children with leukemia. J Pediatr 1977; 90: 1019-21.
24. Allegra CJ. Antifolates. In: Chabner BA, Collins JM, eds. Cancer chemotherapy: Principles and practice. Philadelphia: JB Lippincott Company, 1990: 110-53.
25. Diehl V, Kotz R, Salzer M, et al. Report on various clinical studies on high-dose methotrexate in Europe (NON-EORTC). Onkologie 1981; 4: 308-19.
26. Frickel C, Wolfrom C, Belz S, Henze G. Pharmacokinetics of MTX, 7-OHMTX and rescue folates in HDMTX treatment with low leucovorin rescue. Proc Med Pediatr Oncol 1993; 21: 568 (abstr P55).
27. Lankelma J, Van-der-Klein E, Ramaekers F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett 1980; 9: 133-42.
28. Erttmann R, Bielack S, Landbeck G. Kinetics of 7-hydroxymethotrexate after high-dose methotrexate. Cancer Chemother Pharmacol 1985; 15: 101-4.
29. Bremnes RM, Smeland E, Huseby NE, Eide TJ, Aarbakke J. Acute hepatotoxicity after high-dose methotrexate administration to rats. Pharmacol Toxicol 1991; 69: 132-9.
30. Smeland E, Bremnes RM, Andersen A, et al. Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. Cancer Chemother Pharmacol 1994; 34: 119-24.
31. Fabre G, Matherly LH, Fabre I, Cano JP, Goldman ID. Interactions between 7-hydroxymethotrexate and methotrexate at the cellular level in the Ehrlich ascites tumor in vitro. Cancer Res 1984; 44: 970-5.
32. Chello PL, Sirotnak FM, Dorick DM, Donsbach RC. Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells. Cancer Res 1977; 37: 4297-303.